Is induction therapy necessary for successful simultaneous pancreas and kidney transplantation in the cyclosporine era?
Brayman
K L
KL
Department of Surgery, University of Pennsylvania Medical Center, Philadelphia 19104.
Egidi
M F
MF
Naji
A
A
Friedman
A L
AL
Holland
M T
MT
Tomaszewski
J E
JE
Samini
F
F
Perloff
J
J
Grossman
R
R
Barker
C F
CF
D000328:Adult; D000961:Antilymphocyte Serum / Q000008:administration & dosage / Q000627:therapeutic use; D001379:Azathioprine / Q000008:administration & dosage / Q000627:therapeutic use; D016572:Cyclosporine / Q000008:administration & dosage / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000601:surgery*; D003928:Diabetic Nephropathies / Q000601:surgery*; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000209:etiology; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007676:Kidney Failure, Chronic / Q000601:surgery; D016030:Kidney Transplantation / Q000276:immunology*; D016035:Pancreas Transplantation / Q000276:immunology*; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D012189:Retrospective Studies; D013997:Time Factors
D000961:Antilymphocyte Serum; D016572:Cyclosporine; D001379:Azathioprine; D011241:Prednisone